U.S. Markets open in 9 hrs 3 mins
  • S&P Futures

    4,575.75
    0.00 (0.00%)
     
  • Dow Futures

    34,663.00
    +41.00 (+0.12%)
     
  • Nasdaq Futures

    15,976.00
    -12.50 (-0.08%)
     
  • Russell 2000 Futures

    2,200.00
    -5.20 (-0.24%)
     
  • Crude Oil

    67.76
    +1.26 (+1.89%)
     
  • Gold

    1,772.60
    +9.90 (+0.56%)
     
  • Silver

    22.41
    +0.09 (+0.42%)
     
  • EUR/USD

    1.1299
    -0.0006 (-0.0565%)
     
  • 10-Yr Bond

    1.4480
    -1.4340 (-100.00%)
     
  • Vix

    27.95
    -31.12 (-100.00%)
     
  • GBP/USD

    1.3291
    -0.0011 (-0.0824%)
     
  • USD/JPY

    113.2300
    +0.0210 (+0.0186%)
     
  • BTC-USD

    56,564.25
    -340.38 (-0.60%)
     
  • CMC Crypto 200

    1,439.69
    +0.80 (+0.06%)
     
  • FTSE 100

    7,129.21
    -39.47 (-0.55%)
     
  • Nikkei 225

    27,897.82
    +144.45 (+0.52%)
     

Why Investors Should Love Pfizer's Acquisition of Trillium

·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Pfizer (NYSE: PFE) announced in August that it plans to acquire Trillium Therapeutics (NASDAQ: TRIL) for nearly $2.3 billion. In this Motley Fool Live video recorded on Aug. 25, Motley Fool contributors Keith Speights and Brian Orelli discuss why investors should love Pfizer's latest deal. Pfizer has already started to put some of its growing cash stockpile to use.